Executive Summary
Three high-value civilian federal contracts totaling $259,112,045 obligation (0/3 defense-related) highlight diverse non-defense spending: NASA's $94.6M historical award to LJT & Associates for space launch support (neutral signal), HHS/BARDA's $92.5M bullish R&D grant to Basilea Pharmaceutica International Ltd for antimicrobials, and State Department's $72.0M ongoing IT delivery order to IDEMIA National Security Solutions LLC for facial recognition integration. Dominant sector theme is civilian R&D and tech services, with BARDA health preparedness as the standout. Highest-conviction signal is bullish long-term funding for Basilea ($92.5M obligated, potential $267.6M ceiling to 2035). Key risk is low outlay progress across contracts (e.g., only $8.8M of LJT's $94.6M and $36.2M of Basilea's $92.5M disbursed), warranting watches on option exercises and performance milestones.
Tracking the trend? Catch up on the prior High-Value Federal Grants ($5M+) digest from April 28, 2026.
Investment Signals(3)
- Basilea Pharmaceutica Wins $92.5M BARDA R&D Contract for Antimicrobials(HIGH)▲
HHS/BARDA awarded Basilea Pharmaceutica International Ltd a $92,501,232 cost-sharing contract (ceiling $267.6M with options) on 2024-09-18 for antimicrobials R&D against resistant infections, with performance to 2031-09-30 (potential 2035-12-31) and $36.2M outlayed to date under full competition.
- IDEMIA's $72M State Dept Facial Recognition Order Nears 2026 Completion(MEDIUM)▲
IDEMIA National Security Solutions LLC holds a $72,032,459 firm fixed price delivery order (ceiling $74.1M) from State Department since 2018-09-25 for visa/passport facial recognition integration, with $18.2M outlayed and performance through 2026-09-29.
- LJT & Associates' $94.6M NASA Contract Shows Minimal Outlay Progress(HIGH)▲
LJT & Associates' $94,578,354 cost-plus fixed fee NASA Goddard contract for Wallops Island launch operations (2016-2019) has only $8.8M outlayed against obligation, signaling limited revenue realization from this historical award.
Risk Flags(3)
- Execution[MEDIUM RISK]▼
Basilea Pharmaceutica's $92.5M BARDA contract carries R&D execution risks tied to performance milestones through 2031-09-30 or 2035-12-31, with only $36.2M outlayed to date.
- Budget[HIGH RISK]▼
LJT & Associates' $94.6M NASA contract ended in 2019 with just $8.8M outlayed, indicating budget absorption issues and no evident follow-on.
- Execution[MEDIUM RISK]▼
IDEMIA's $72.0M State Department order faces high firm fixed price risk, with only $18.2M outlayed over 8 years to 2026-09-29.
Opportunities(2)
- ◆
Basilea Pharmaceutica's $92.5M BARDA award offers expansion via unexercised options to $267.6M for antimicrobials R&D.
- ◆
IDEMIA National Security Solutions LLC has $2.1M in remaining options on $72.0M State Department facial recognition order.
Sector Themes(3)
- ◆
HHS/BARDA's $92.5M cost-sharing award to Basilea Pharmaceutica (NAICS 541714, PSC AN42) underscores priority funding for antimicrobials against resistant infections, with 7-11 year visibility.
- ◆
NASA Goddard's $94.6M non-competed award to LJT & Associates (PSC AJ45) supported Wallops Island launches through 2019, but low $8.8M outlay signals waning momentum.
- ◆
State Department's $72.0M delivery order to IDEMIA (PSC 7030) integrates facial recognition for visas/passports through 2026.
Watch List(3)
- 👁
{"entity"=>"Basilea Pharmaceutica International Ltd", "reason"=>"$92.5M BARDA obligation with $36.2M outlayed; potential $267.6M ceiling", "trigger"=>"option exercises; outlay progress; milestones to 2031-09-30 or 2035-12-31"}
- 👁
{"entity"=>"IDEMIA National Security Solutions LLC", "reason"=>"$72.0M State Dept obligation with $18.2M outlayed; runs to 2026-09-29", "trigger"=>"outlay progress; option exercises toward $74.1M"}
- 👁
{"entity"=>"LJT & Associates, Inc.", "reason"=>"$94.6M NASA obligation with only $8.8M outlayed post-2019 end", "trigger"=>"follow-on contracts; status of options to $108.1M"}
Get daily alerts with 3 investment signals, 3 risk alerts, 2 opportunities and full AI analysis of all 3 filings
More from: High-Value Federal Grants ($5M+)
🇺🇸 More from United States
View all →April 30, 2026
US Pre-Market SEC Filings Roundup — April 30, 2026
US Pre-Market SEC Filings Roundup
April 29, 2026
US Pre-Market SEC Filings Roundup — April 29, 2026
US Pre-Market SEC Filings Roundup
April 29, 2026
US Activist Hedge Fund Institutional SEC 13D 13G — April 29, 2026
US Activist Hedge Fund Institutional SEC 13D 13G
April 29, 2026
Nasdaq 100 Stocks SEC Filings — April 29, 2026
Nasdaq 100 Stocks SEC Filings